Irish manufacturing rebounded 12.1% in May, nearly erasing April’s slump, as U.S. demand for Irish-made pharmaceuticals surged, driven by both stockpiling ahead of possible tariffs and booming interest in weight-loss and diabetes treatments.

Exports to the U.S. jumped by $2.5 billion, reinforcing Ireland’s role as a key supplier of critical healthcare products. The pharma sector’s resilience is also bolstering eurozone economic hopes amid global trade shifts. 

Read the full story for insights on what’s driving the bounce.